Phenotyping and Visualizing Infusion-Related Reactions for Breast Cancer Patients
- PMID: 29295166
- PMCID: PMC5760174
Phenotyping and Visualizing Infusion-Related Reactions for Breast Cancer Patients
Abstract
Infusion-related reactions (IRRs) are typical adverse events for breast cancer patients. Detecting IRRs and visualizing their occurance associated with the drug treatment would potentially assist clinicians to improve patient safety and help researchers model IRRs and analyze their risk factors. We developed and evaluated a phenotyping algorithm to detect IRRs for breast cancer patients. We also designed a visualization prototype to render IRR patients' medications, lab tests and vital signs over time. By comparing with the 42 randomly selected doses that are manually labeled by a domain expert, the sensitivity, positive predictive value, specificity, and negative predictive value of the algorithms are 69%, 60%, 79%, and 85%, respectively. Using the algorithm, an incidence of 6.4% of patients and 1.8% of doses for docetaxel, 8.7% and 3.2% for doxorubicin, 10.4% and 1.2% for paclitaxel, 16.1% and 1.1% for trastuzumab were identified retrospectively. The incidences estimated are consistent with related studies.
Keywords: Algorithms; Patient Safety; Phenotype.
Figures
Similar articles
-
Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab.Oncologist. 2014 Mar;19(3):228-34. doi: 10.1634/theoncologist.2013-0286. Epub 2014 Feb 17. Oncologist. 2014. PMID: 24536030 Free PMC article.
-
Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.Onkologie. 2005 Nov;28(11):558-64. doi: 10.1159/000088608. Onkologie. 2005. PMID: 16249641 Clinical Trial.
-
Preventive effect of dexamethasone premedication on the development of infusion-related reaction in breast cancer patients receiving trastuzumab.Br J Clin Pharmacol. 2023 Jul;89(7):2102-2112. doi: 10.1111/bcp.15675. Epub 2023 Feb 9. Br J Clin Pharmacol. 2023. PMID: 36709967
-
Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when.Future Oncol. 2008 Feb;4(1):125-31. doi: 10.2217/14796694.4.1.125. Future Oncol. 2008. PMID: 18241007 Review.
-
Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force.Cancer Treat Rev. 2016 Feb;43:19-26. doi: 10.1016/j.ctrv.2015.11.009. Epub 2015 Dec 15. Cancer Treat Rev. 2016. PMID: 26827689 Review.
References
-
- Kumar V, Abbas AK, Fausto N, Robbins SL, Cotran RS. Robbins and Cotran pathologic basis of disease. 7. Philadelphia: Elsevier Sauders; 2005.
-
- Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol. 2005;5:309–316. - PubMed
-
- Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Alimentary pharmacology and therapeutics. 2003;17:75–84. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
